Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, John Mark Sloan, MD, Anas Younes, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 5212.

https://doi.org/10.1182/blood.V130.Suppl_1.5212.5212

Published: 2017

Journal Articles

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, Anas Younes, MD

Blood (2016) 128 (22): 4200.

https://doi.org/10.1182/blood.V128.22.4200.4200

Published: 2016

Journal Articles

Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Catherine S. Diefenbach, MD, David J. Valacer, MD, Jack Higgins, PhD, Michelle A. Fanale

Blood (2015) 126 (23): 5112.

https://doi.org/10.1182/blood.V126.23.5112.5112

Published: 2015

Journal Articles

Shiga Toxin 1(Stx1) Stimulates Endothelial Cell VWF Secretion through a Ca 2+ /PKC Signaling Pathway That Does Not Require the Active Toxin Stx1A Subunit

Fang Liu, MD, PhD, Jing Huang, PhD, MD, J. Evan Sadler, MD, PhD

Blood (2008) 112 (11): 3931.

https://doi.org/10.1182/blood.V112.11.3931.3931

Published: 2008

Journal Articles

Verotoxin-1–induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress

Marina Morigi, Miriam Galbusera, Elena Binda, Barbara Imberti, Sara Gastoldi, Andrea Remuzzi, Carla Zoja, Giuseppe Remuzzi

Blood (2001) 98 (6): 1828–1835.

https://doi.org/10.1182/blood.V98.6.1828

Published: 2001

NARROW

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL)

Shiga Toxin 1(Stx1) Stimulates Endothelial Cell VWF Secretion through a Ca 2+ /PKC Signaling Pathway That Does Not Require the Active Toxin Stx1A Subunit

Verotoxin-1–induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress

Email alerts

ASH Publications

American Society of Hematology

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL)

Shiga Toxin 1(Stx1) Stimulates Endothelial Cell VWF Secretion through a Ca 2+ /PKC Signaling Pathway That Does Not Require the Active Toxin Stx1A Subunit

Verotoxin-1–induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only